Derik De Bruin
Stock Analyst at B of A Securities
(3.58)
# 829
Out of 5,245 analysts
206
Total ratings
64.96%
Success rate
13.48%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $21 → $30 | $23.68 | +26.69% | 10 | Apr 20, 2026 | |
| WAT Waters | Maintains: Neutral | $410 → $350 | $342.37 | +2.23% | 15 | Feb 10, 2026 | |
| BRKR Bruker | Maintains: Buy | $43 → $60 | $45.69 | +31.32% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $114.96 | +43.53% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,103.09 | +26.01% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $172.00 | +27.91% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $33.26 | -18.82% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $96.95 | +13.46% | 3 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $48 → $50 | $35.17 | +43.53% | 6 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $3.81 | +188.71% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $9.23 | +73.35% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $448.28 | +47.23% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $167.90 | +39.96% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $160.30 | +31.00% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $316.42 | +12.19% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $18.01 | +44.36% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $259.93 | +4.26% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $195.21 | -6.77% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $13.22 | +58.85% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $13.30 | +140.60% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $144.41 | -30.75% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.03 | +329.04% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.79 | +263.13% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $116.78 | +122.64% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $8.41 | +1,326.87% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $81.32 | +47.57% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $3.15 | +185.71% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $559.37 | -57.99% | 3 | Nov 2, 2018 |
10x Genomics
Apr 20, 2026
Maintains: Neutral
Price Target: $21 → $30
Current: $23.68
Upside: +26.69%
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $410 → $350
Current: $342.37
Upside: +2.23%
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $45.69
Upside: +31.32%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $114.96
Upside: +43.53%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,103.09
Upside: +26.01%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $172.00
Upside: +27.91%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $33.26
Upside: -18.82%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $96.95
Upside: +13.46%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $48 → $50
Current: $35.17
Upside: +43.53%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $3.81
Upside: +188.71%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $9.23
Upside: +73.35%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $448.28
Upside: +47.23%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $167.90
Upside: +39.96%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $160.30
Upside: +31.00%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $316.42
Upside: +12.19%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $18.01
Upside: +44.36%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $259.93
Upside: +4.26%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $195.21
Upside: -6.77%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $13.22
Upside: +58.85%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $13.30
Upside: +140.60%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $144.41
Upside: -30.75%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.03
Upside: +329.04%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.79
Upside: +263.13%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $116.78
Upside: +122.64%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $8.41
Upside: +1,326.87%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $81.32
Upside: +47.57%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $3.15
Upside: +185.71%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $559.37
Upside: -57.99%